These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 36017746)

  • 1. Application of Neuromelanin MR Imaging in Parkinson Disease.
    He N; Chen Y; LeWitt PA; Yan F; Haacke EM
    J Magn Reson Imaging; 2023 Feb; 57(2):337-352. PubMed ID: 36017746
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnosing Parkinson's disease by combining neuromelanin and iron imaging features using an automated midbrain template approach.
    Jokar M; Jin Z; Huang P; Wang Y; Zhang Y; Li Y; Cheng Z; Liu Y; Tang R; Shi X; Min J; Liu F; Chen S; He N; Haacke EM; Yan F
    Neuroimage; 2023 Feb; 266():119814. PubMed ID: 36528314
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Imaging iron and neuromelanin simultaneously using a single 3D gradient echo magnetization transfer sequence: Combining neuromelanin, iron and the nigrosome-1 sign as complementary imaging biomarkers in early stage Parkinson's disease.
    He N; Ghassaban K; Huang P; Jokar M; Wang Y; Cheng Z; Jin Z; Li Y; Sethi SK; He Y; Chen Y; Gharabaghi S; Chen S; Yan F; Haacke EM
    Neuroimage; 2021 Apr; 230():117810. PubMed ID: 33524572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased iron-deposition in lateral-ventral substantia nigra pars compacta: A promising neuroimaging marker for Parkinson's disease.
    He N; Langley J; Huddleston DE; Chen S; Huang P; Ling H; Yan F; Hu X
    Neuroimage Clin; 2020; 28():102391. PubMed ID: 32889398
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Automatic detection of neuromelanin and iron in the midbrain nuclei using a magnetic resonance imaging-based brain template.
    Jin Z; Wang Y; Jokar M; Li Y; Cheng Z; Liu Y; Tang R; Shi X; Zhang Y; Min J; Liu F; He N; Yan F; Haacke EM
    Hum Brain Mapp; 2022 Apr; 43(6):2011-2025. PubMed ID: 35072301
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Parkinson's disease-related increase of T2*-weighted hypointensity in substantia nigra pars compacta.
    Langley J; Huddleston DE; Sedlacik J; Boelmans K; Hu XP
    Mov Disord; 2017 Mar; 32(3):441-449. PubMed ID: 28004859
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantifying changes in nigrosomes using quantitative susceptibility mapping and neuromelanin imaging for the diagnosis of early-stage Parkinson's disease.
    Takahashi H; Watanabe Y; Tanaka H; Mihara M; Mochizuki H; Liu T; Wang Y; Tomiyama N
    Br J Radiol; 2018 Jun; 91(1086):20180037. PubMed ID: 29498540
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo detection of lateral-ventral tier nigral degeneration in Parkinson's disease.
    Huddleston DE; Langley J; Sedlacik J; Boelmans K; Factor SA; Hu XP
    Hum Brain Mapp; 2017 May; 38(5):2627-2634. PubMed ID: 28240402
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A distinct neuromelanin magnetic resonance imaging pattern in parkinsonian multiple system atrophy.
    Simões RM; Castro Caldas A; Grilo J; Correia D; Guerreiro C; Pita Lobo P; Valadas A; Fabbri M; Correia Guedes L; Coelho M; Rosa MM; Ferreira JJ; Reimão S
    BMC Neurol; 2020 Nov; 20(1):432. PubMed ID: 33243166
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imaging the Nigrosome 1 in the substantia nigra using susceptibility weighted imaging and quantitative susceptibility mapping: An application to Parkinson's disease.
    Cheng Z; He N; Huang P; Li Y; Tang R; Sethi SK; Ghassaban K; Yerramsetty KK; Palutla VK; Chen S; Yan F; Haacke EM
    Neuroimage Clin; 2020; 25():102103. PubMed ID: 31869769
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comprehensive MRI quantification of the substantia nigra pars compacta in Parkinson's disease.
    Takahashi H; Watanabe Y; Tanaka H; Mihara M; Mochizuki H; Takahashi K; Yamamoto K; Liu T; Wang Y; Tomiyama N
    Eur J Radiol; 2018 Dec; 109():48-56. PubMed ID: 30527311
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In Vivo Assessment of Brainstem Depigmentation in Parkinson Disease: Potential as a Severity Marker for Multicenter Studies.
    Schwarz ST; Xing Y; Tomar P; Bajaj N; Auer DP
    Radiology; 2017 Jun; 283(3):789-798. PubMed ID: 27820685
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Longitudinal Changes in Neuromelanin MRI Signal in Parkinson's Disease: A Progression Marker.
    Gaurav R; Yahia-Cherif L; Pyatigorskaya N; Mangone G; Biondetti E; Valabrègue R; Ewenczyk C; Hutchison RM; Cedarbaum JM; Corvol JC; Vidailhet M; Lehéricy S
    Mov Disord; 2021 Jul; 36(7):1592-1602. PubMed ID: 33751655
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuromelanin-sensitive magnetic resonance imaging features of the substantia nigra and locus coeruleus in de novo Parkinson's disease and its phenotypes.
    Wang J; Li Y; Huang Z; Wan W; Zhang Y; Wang C; Cheng X; Ye F; Liu K; Fei G; Zeng M; Jin L
    Eur J Neurol; 2018 Jul; 25(7):949-e73. PubMed ID: 29520900
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo detection of substantia nigra and locus coeruleus volume loss in Parkinson's disease using neuromelanin-sensitive MRI: Replication in two cohorts.
    Hwang KS; Langley J; Tripathi R; Hu XP; Huddleston DE
    PLoS One; 2023; 18(4):e0282684. PubMed ID: 37053195
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multimodal assessment of nigrosomal degeneration in Parkinson's disease.
    Langley J; Huddleston DE; Crosson B; Song DD; Factor SA; Hu X
    Parkinsonism Relat Disord; 2020 Nov; 80():102-107. PubMed ID: 32979784
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regional Selectivity of Neuromelanin Changes in the Substantia Nigra in Atypical Parkinsonism.
    Chougar L; Arsovic E; Gaurav R; Biondetti E; Faucher A; Valabrègue R; Pyatigorskaya N; Dupont G; Lejeune FX; Cormier F; Corvol JC; Vidailhet M; Degos B; Grabli D; Lehéricy S
    Mov Disord; 2022 Jun; 37(6):1245-1255. PubMed ID: 35347754
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuromelanin imaging and midbrain volumetry in progressive supranuclear palsy and Parkinson's disease.
    Taniguchi D; Hatano T; Kamagata K; Okuzumi A; Oji Y; Mori A; Hori M; Aoki S; Hattori N
    Mov Disord; 2018 Sep; 33(9):1488-1492. PubMed ID: 29756366
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 7 Tesla magnetic resonance imaging: a closer look at substantia nigra anatomy in Parkinson's disease.
    Lehéricy S; Bardinet E; Poupon C; Vidailhet M; François C
    Mov Disord; 2014 Nov; 29(13):1574-81. PubMed ID: 25308960
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Imaging the Substantia Nigra in Parkinson Disease and Other Parkinsonian Syndromes.
    Bae YJ; Kim JM; Sohn CH; Choi JH; Choi BS; Song YS; Nam Y; Cho SJ; Jeon B; Kim JH
    Radiology; 2021 Aug; 300(2):260-278. PubMed ID: 34100679
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.